GlobeImmune Files for $69-Million IPO
GlobeImmune, Inc. recently announced it has publicly filed a registration statement with the US SEC relating to a proposed initial public offering of shares of its common stock. GlobeImmune previously submitted its registration statement to the SEC on a confidential basis under the Jumpstart Our Business Startups Act. The number of shares to be offered and the price range for the offering have not been determined. The company has filed an application for its common stock to be listed on the NASDAQ Global Market under the symbol GBIM.
Wells Fargo Securities, LLC, and Piper Jaffray & Co. will act as joint book-running managers for the offering. JMP Securities, LLC, will act as co-manager. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. The offering will be made only by means of a prospectus.
GlobeImmune is a biopharmaceutical company focused on developing therapeutic products for cancer and infectious diseases based on its proprietary Tarmogen platform. Tarmogens activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines, which stimulate predominately antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications and are efficient to manufacture.
In May 2009, the company entered into a collaboration agreement with Celgene Corporation focused on the discovery, development, and commercialization of product candidates for the treatment of cancer. In October 2011, the company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens for the treatment of chronic hepatitis B infection. For more information, visit www.globeimmune.com.
Total Page Views: 946
